Lumos Diagnostics Hldgs Valuation Multiples

Lumos Diagnostics Hldgs is valued at $67M as of October 2026, a 3.8x revenue multiple. In the last 12 months, Lumos Diagnostics Hldgs revenue was $15M and Lumos Diagnostics Hldgs EBITDA was ($6M).

Lumos Diagnostics Hldgs Overview

About Lumos Diagnostics Hldgs

Lumos Diagnostics Holdings Ltd is engaged in the development, manufacture, and distribution of point-of-care diagnostic (POC) tests and associated readers for analysis of POC diagnostic tests. The group is dedicated to providing contract research and development services, focusing on the innovation, development, manufacturing, and commercialization of point-of-care diagnostic solutions for both clinical and consumer applications. It generates maximum revenue from commercial services and solutions relating to POC diagnostic tests. The group has one operating segment, which is the provision of point-of-care diagnostics goods and services. The Company operates in two geographical regions, the United States and Australia and the majority of revenue is generated from the United States.


Founded

2018

HQ

United States

Employees

110

Financials (LTM)

Revenue: $15M
EBITDA: ($6M)

EV

$58M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Lumos Diagnostics Hldgs Financials

Lumos Diagnostics Hldgs reported last 12-month revenue of $15M and negative EBITDA of ($6M).

In the same LTM period, Lumos Diagnostics Hldgs generated $9M in gross profit, ($6M) in EBITDA losses, and had net loss of ($6M).

Revenue (LTM)


Lumos Diagnostics Hldgs P&L

In the most recent fiscal year, Lumos Diagnostics Hldgs reported revenue of $13M and EBITDA of ($412K).

Lumos Diagnostics Hldgs is unprofitable as of last fiscal year, with gross margin of 60%, EBITDA margin of (3%), and net margin of (38%).

See analyst estimates for Lumos Diagnostics Hldgs
LTMLast FY202620272028
Revenue$15M$13M
Gross Profit$9M$8M
Gross Margin61%60%
EBITDA($6M)($412K)
EBITDA Margin(37%)(3%)
EBIT Margin(61%)(107%)
Net Profit($6M)($5M)
Net Margin(39%)(38%)
Net Debt-($9M)

Financial data powered by Morningstar, Inc.

Lumos Diagnostics Hldgs Stock Performance

Lumos Diagnostics Hldgs has current market cap of $67M, and enterprise value of $58M.

Market Cap Evolution


Lumos Diagnostics Hldgs' stock price is $0.07.

Lumos Diagnostics Hldgs share price decreased by 1.0% in the last 30 days, and by 48.3% in the last year.

Lumos Diagnostics Hldgs has an EPS (earnings per share) of $-0.01.

See more trading valuation data for Lumos Diagnostics Hldgs
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$58M$67M-0.0%-1.0%-0.9%-48.3%$-0.01

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Lumos Diagnostics Hldgs Valuation Multiples

Lumos Diagnostics Hldgs trades at 3.8x EV/Revenue multiple, and (10.2x) EV/EBITDA.

See NTM and 2027E valuation multiples for Lumos Diagnostics Hldgs

EV / Revenue (LTM)


Lumos Diagnostics Hldgs Financial Valuation Multiples

As of October 5, 2026, Lumos Diagnostics Hldgs has market cap of $67M and EV of $58M.

Lumos Diagnostics Hldgs has a P/E ratio of (11.3x).

LTMLast FY202620272028
EV/Revenue3.8x4.4x
EV/EBITDA(10.2x)(140.5x)
EV/EBIT(6.2x)(4.1x)
EV/Gross Profit6.2x7.3x
P/E(11.3x)(13.6x)
EV/FCF(13.6x)(38.0x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Lumos Diagnostics Hldgs Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Lumos Diagnostics Hldgs Margins & Growth Rates

Lumos Diagnostics Hldgs grew revenue by 60% and EBITDA by 1123% in the last fiscal year.

In the most recent fiscal year, Lumos Diagnostics Hldgs reported gross margin of 60%, EBITDA margin of (3%), and net margin of (38%).

See estimated margins and future growth rates for Lumos Diagnostics Hldgs

Lumos Diagnostics Hldgs Margins

Last FY2026202720282029
Gross Margin60%62%
EBITDA Margin(3%)(16%)
EBIT Margin(107%)(67%)
Net Margin(38%)(40%)
FCF Margin(12%)(37%)

Lumos Diagnostics Hldgs Growth Rates

FY+1/FY26/2727/2828/29
Revenue Growth60%
Gross Profit Growth67%
EBITDA Growth1123%
EBIT Growth(37%)
Net Profit Growth77%
FCF Growth622%

Data powered by FactSet, Inc. and Morningstar, Inc.

Lumos Diagnostics Hldgs Operational KPIs

Lumos Diagnostics Hldgs' revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.2M for the same period.

Access forward-looking KPIs for Lumos Diagnostics Hldgs
LTMLast FY202620272028
Rule of 4019%-
Bessemer Rule of X104%-
Revenue per Employee-$0.1M
Opex per Employee-$0.2M
S&M Expenses to Revenue9%6%
G&A Expenses to Revenue34%31%
R&D Expenses to Revenue3%3%
Opex to Revenue-167%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Lumos Diagnostics Hldgs Competitors

Lumos Diagnostics Hldgs competitors include Austco Healthcare, Osang Healthcare, Fractyl Health, Myomo, Medicalgorithmics, iNtRON Biotechnology, RenovoRx, Meta Biomed, Daxor and Saluda Medical.

Most Lumos Diagnostics Hldgs public comparables operate across Medical Devices, Diagnostics & Genomics, BioTech and DeepTech.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Austco Healthcare$65M$11M0.9x0.8x5.2x5.3x
Osang Healthcare$95M$8M0.7x-8.2x-
Fractyl Health-($141M)--(0.6x)(1.0x)
Myomo$41M($13M)1.7x1.6x(5.6x)(9.8x)
Medicalgorithmics$8M($1M)8.8x6.2x(54.2x)61.2x
iNtRON Biotechnology$4M($6M)9.6x-(7.0x)-
RenovoRx$1M($12M)55.4x19.3x(5.4x)-
Meta Biomed$76M$15M1.0x1.1x5.3x2.0x

This data is available for Pro users. Sign up to see all Lumos Diagnostics Hldgs competitors and their valuation data.

Start Free Trial

Lumos Diagnostics Hldgs VC Funding History

Before going public, Lumos Diagnostics Hldgs raised $40M in total equity funding, across 3 rounds.


Lumos Diagnostics Hldgs Funding Rounds

DateStageInvestorsRaisedValuationRev. MultipleDeal Summary
Sep-24Strategic investmentTenmile$7M-Lumos Diagnostics announced a fully underwritten A$10 million equity raising and welcomed Tenmile Ventures as a new shareholder on 4 September 2024. The transaction combined Tenmile's acquisition of an existing stake with its support for the issuer's accelerated entitlement offer, making the round a strategic investment in a listed growth company rather than a conventional private Series A or B. Lumos said proceeds would fund completion of the United States FebriDx CLIA-waiver study, product development, sales and marketing, general working capital and transaction costs. FebriDx is a rapid point-of-care blood test designed to distinguish bacterial from viral acute respiratory infections and help clinicians make better antibiotic decisions. Lumos also develops and manufactures diagnostic assays and reader systems for commercial partners. The company emerged from a combination involving Planet Innovation's diagnostics activities and RPS Diagnostics and later listed on the ASX. Tenmile's participation fits its focus on diagnostics and antimicrobial resistance, because faster infection triage can reduce inappropriate antibiotic prescribing. Public disclosures identify the total offer size in native Australian dollars but do not isolate the value of all shares ultimately subscribed by Tenmile within the raise. The A$10 million figure is therefore the issuer's aggregate capital raising, not a claim that Tenmile funded the whole amount. Tenmile and Ryder Capital later offered a separate A$5 million secured loan facility in 2025, which is not merged into this equity event. The database contains Lumos's 2020 Series A and growth financings but no 2024 transaction, so this finding is collision-safe.
Oct-20Undisclosed stageRegal Investment Fund$18M--
Feb-20Series APlanet Innovation$15M-Lumos Diagnostics secured US$15 million in Series A funding from Planet Innovation on February 5, 2020. The funding supported international commercial expansion of the FebriDx rapid point-of-care test, the U.S. FDA pivotal clinical trial, and additional development and manufacturing resources for its point-of-care business. Lumos Diagnostics, a spinout from Planet Innovation that merged with RPS Diagnostics in May 2019, provides rapid point-of-care diagnostic test solutions using proprietary digital reader platforms for infectious and inflammatory diseases.

Acquisitions by Lumos Diagnostics Hldgs

Lumos Diagnostics Hldgs has acquired 1 company to date.

Last acquisition by Lumos Diagnostics Hldgs was on May 29th 2019. Lumos Diagnostics Hldgs acquired Rapid Pathogen Screening for undisclosed valuation.

See M&A valuation multiples

Latest Acquisitions by Lumos Diagnostics Hldgs

Rapid Pathogen Screening
Description
Rapid Pathogen Screening is a developer and marketer of point-of-care diagnostic tests for infectious diseases. Florida-headquartered, the company produces rapid tests for conjunctivitis pathogens like adenovirus and Streptococcus, deliverable in 10 minutes without lab equipment. Its patented platform also supports U.S. government contracts for biothreat and nerve agent detection. Founded in 2004, Rapid Pathogen Screening targets clinician offices with high-sensitivity assays for inflammatory conditions.
HQ CountryUnited States
HQ City
Sarasota, FL
Deal Date29 May 2019
Valuationundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Lumos Diagnostics Hldgs acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Lumos Diagnostics Hldgs

When was Lumos Diagnostics Hldgs founded?Lumos Diagnostics Hldgs was founded in 2018.
Where is Lumos Diagnostics Hldgs headquartered?Lumos Diagnostics Hldgs is headquartered in United States.
How many employees does Lumos Diagnostics Hldgs have?As of today, Lumos Diagnostics Hldgs has over 110 employees.
Is Lumos Diagnostics Hldgs publicly listed?Yes, Lumos Diagnostics Hldgs is a public company listed on Australian Securities Exchange.
What is the stock symbol of Lumos Diagnostics Hldgs?Lumos Diagnostics Hldgs trades under LDX ticker.
When did Lumos Diagnostics Hldgs go public?Lumos Diagnostics Hldgs went public in 2021.
Who are competitors of Lumos Diagnostics Hldgs?Lumos Diagnostics Hldgs main competitors include Austco Healthcare, Osang Healthcare, Fractyl Health, Myomo, Medicalgorithmics, iNtRON Biotechnology, RenovoRx, Meta Biomed, Daxor, Saluda Medical.
What is the current market cap of Lumos Diagnostics Hldgs?Lumos Diagnostics Hldgs' current market cap is $67M.
What is the current revenue of Lumos Diagnostics Hldgs?Lumos Diagnostics Hldgs' last 12 months revenue is $15M.
What is the current revenue growth of Lumos Diagnostics Hldgs?Lumos Diagnostics Hldgs revenue growth (NTM/LTM) is 56%.
What is the current EV/Revenue multiple of Lumos Diagnostics Hldgs?Current revenue multiple of Lumos Diagnostics Hldgs is 3.8x.
Is Lumos Diagnostics Hldgs profitable?No, Lumos Diagnostics Hldgs is not profitable.
What is the current EBITDA of Lumos Diagnostics Hldgs?Lumos Diagnostics Hldgs has negative EBITDA and is not profitable.
What is Lumos Diagnostics Hldgs' EBITDA margin?Lumos Diagnostics Hldgs' last 12 months EBITDA margin is (37%).
What is the current EV/EBITDA multiple of Lumos Diagnostics Hldgs?Current EBITDA multiple of Lumos Diagnostics Hldgs is (10.2x).
What is the current FCF of Lumos Diagnostics Hldgs?Lumos Diagnostics Hldgs' last 12 months FCF is ($4M).
What is Lumos Diagnostics Hldgs' FCF margin?Lumos Diagnostics Hldgs' last 12 months FCF margin is (28%).
What is the current EV/FCF multiple of Lumos Diagnostics Hldgs?Current FCF multiple of Lumos Diagnostics Hldgs is (13.6x).
How many companies Lumos Diagnostics Hldgs has acquired to date?As of October 2026, Lumos Diagnostics Hldgs has acquired 1 company.
What was the largest acquisition by Lumos Diagnostics Hldgs?None of the M&A deals Lumos Diagnostics Hldgs has completed have disclosed valuations.
What companies Lumos Diagnostics Hldgs acquired?Lumos Diagnostics Hldgs acquired Rapid Pathogen Screening.
In how many companies Lumos Diagnostics Hldgs has invested to date?Lumos Diagnostics Hldgs hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Lumos Diagnostics Hldgs

Lists including Lumos Diagnostics Hldgs

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial